Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WEDGE-MAVA in hypertrophic cardiomyopathy
2026-527595-90-00Phase 4Withdrawn
- Sponsor
- Capital Region of Denmark
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of mavacamten in hypertrophic cardiomyopathy (HCM), sponsored by Capital Region of Denmark. Primary endpoint: Change in pulmonary capillary wedge pressure at 25 W. Planned start Oct 2026; status: withdrawn.
02
Drugs
mavacamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on 2026-527595-90-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-527595-90-00.